a monoclonal antibody being studied in the treatment of melanoma and some other types of cancer. ticilimumab is made in the laboratory and binds to a protein called ctla-4 on t cells (a type of white blood cell). ctla-4 is involved in preventing the activation of t-cells. ticilimumab may block ctla-4 and help the immune system kill cancer cells. it is a type of immunomodulatory agent.
![]()